RIPK2 and cancer: Another study about pan-cancer analysis of the carcinogenic role of RIPK2 also illustrated that the gene amplification rate of RIPK2 in BRCA and uterine carcinosarcoma (UCS) was approximately 8.5% (Zhang et al., 2022a).